Senda Biosciences
20 Acorn Park Drive, Suite 300
Cambridge
MA
02140
United States
Tel: 617.430.4455
8 articles about Senda Biosciences
-
Sail Biomedicines combines Laronde’s circular eRNA platform with Senda’s nanoparticle delivery technology in the pursuit of a new class of programmable medicines across therapeutic areas.
-
Senda Biosciences Appoints Igor Matushansky as Chief Medical Officer
7/24/2023
Senda Biosciences, Inc. today announced the appointment of Igor Matushansky, M.D., Ph.D., as Chief Medical Officer.
-
Senda Biosciences Appoints Marc Wolfgang as Senior Vice President, Manufacturing
6/12/2023
Senda Biosciences, Inc., a Flagship Pioneering company pioneering programmable medicines, announced the appointment of Marc Wolfgang as Senior Vice President, Manufacturing.
-
Senda Biosciences Appoints Luke O’Neill, Ph.D., as Chief Scientific Officer
1/12/2023
Senda Biosciences, Inc., a company harnessing nature to enable the world’s first comprehensive programming of medicines, today announced the appointment of Luke O’Neill, Ph.D., as Chief Scientific Officer.
-
Senda Biosciences Appoints MIT Institute Professor Paula Hammond, Ph.D., to Its Board of Directors
12/14/2022
Senda Biosciences, Inc. announced the appointment of Paula Hammond, Ph.D., Institute Professor and Head of MIT's Department of Chemical Engineering, to the Company's Board of Directors.
-
Senda Biosciences Bolsters Executive Leadership Team
10/19/2022
Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the appointments of Lori Rudolph-Owen, Ph.D., as Chief Operating Officer, and Barbara Bispham, J.D., as SVP, General Counsel.
-
Senda Biosciences Announces Close of $123 Million Series C Financing
8/16/2022
Senda Biosciences , Inc., a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the completion of a $123 million Series C financing, bringing its total funding raised to date to $266 million.
-
Proceeds from the fund activities will be used to back Senda's proprietary programmable medicines platform and advance its projects to clinical trial stages.